Article

Screening primary care patients for hereditary hemochromatosis with transferring and serum ferritin level: systematic review for the American College of Physicians

Loyola University Medical Center, Maywood, Illinois, USA.
Annals of internal medicine (Impact Factor: 16.1). 11/2005; 143(7):522-36.
Source: PubMed

ABSTRACT Therapeutic phlebotomy for hereditary hemochromatosis is relatively safe and presumably efficacious when offered before cirrhosis develops, so screening primary care patients is of substantial interest.
To conduct a systematic review of the evidence on 1) the prevalence of the disease in primary care, 2) the risk for morbid or fatal complications for untreated patients, 3) the diagnostic usefulness of transferrin saturation and serum ferritin level in identifying early disease, 4) the efficacy of early treatment, and 5) whether the benefits of screening outweigh the risks.
MEDLINE search from 1966 through April 2004, complemented by reference review of identified original studies and review articles published in English.
PubMed Clinical Queries filters search of prognosis, diagnosis, etiology, or treatment were used depending on the question. Two authors reviewed all titles and abstracts.
Two investigators independently reviewed extracted data.
The prevalence of hereditary hemochromatosis was 1 in 169 patients to 1 in 556 patients (n = 3 studies). Uncontrolled, prospective studies of genetic homozygous patients did not consistently identify a link to overt hereditary hemochromatosis. A serum ferritin level less than 1000 microg/L was predictive of absence of cirrhosis. Six studies demonstrated reduced survival in patients with cirrhosis. Diagnostic studies varied with respect to case definition. No blinded, independent comparisons of screening tests with the gold standard (biopsy or results of quantitative phlebotomy) or randomized, controlled trials of phlebotomy were identified. Cost-effectiveness analysis was limited by lack of prospective data on the natural history of the disease.
Varied case definition and lack of prospective cohort studies or randomized trials.
The available evidence does not demonstrate that benefits outweigh the risks and costs of screening for hemochromatosis.

Download full-text

Full-text

Available from: Brian Schmitt, Jun 17, 2015
0 Followers
 · 
91 Views
 · 
16 Downloads
  • Source
    • "The downward pressure on the frequency of C282Y in populations (balanced polymorphism) appears to be small. This further supports the finding of the similar frequencies of the gene in younger and older generations in the same population [11] [26]. The same argument applies to H63D allele, which has a significantly milder phenotype than C282Y allele. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Iron deficiency, with or without iron-deficiency anemia, is so ubiquitous that it affects all populations of the world irrespective of race, culture, or ethnic background. Despite all the latest advances in modern medicine, improved nutrition, and the ready availability of cheap oral iron, there is still no good explanation for the widespread persistence of iron deficiency. It is possible that the iron deficiency phenotype is very prevalent because of many factors other than the commonly cited causes such as a decreased availability or an increased utilization of iron. Several thousand years ago, human culture changed profoundly with the agrarian revolution, when humans turned to agriculture. Their diet became iron deficient and new epidemic infections emerged due to crowding and lifestyle changes. There is convincing evidence that iron deficiency protects against many infectious diseases such as malaria, plague, and tuberculosis as shown by diverse medical, historical, and anthropologic studies. Thus, this change of diet increased the frequency of iron deficiency, and epidemic infections exerted a selection pressure under which the iron deficiency phenotype survived better. Multiple evolutionary factors have contributed in making iron deficiency a successful phenotype. We analyze some of the recent findings of iron metabolism, the theories explaining excessive menstruation in human primates, the unexplained relative paucity of hemochromatosis genes, the former medical practice of "blood-letting," and other relevant historical data to fully understand the phenomenon of iron deficiency. We suggest that, due to a long evolutionary persistence of iron deficiency, efforts at its prevention will take a long time to be effective.
    Nutrition 07/2007; 23(7-8):603-14. DOI:10.1016/j.nut.2007.05.002 · 3.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Iron overload has been associated with HFE mutations (C282Y and H63D). We investigated the association between these mutations and high serum ferritin in a sample of healthy adult men. We enrolled unrelated blood donors from three hospitals in Mexico City in a crosssectional study. Serum ferritin (SF) was determined to define iron overload, and HFE gene mutations were identified by PCR-RFLP. We evaluated 2524 male blood donors and included 246 individuals for each group. We identified 108 individuals with HFE gene mutation, 20.5 % were heterozygote (wt/H63D or wt/C282Y) and the remaining homozygote (H63D/ H63D). The genotype wt/C282Y was observed in two cases, none cases with C282Y/C282Y. The allelic frequency of H63D and C282Y was 0.115 and 0.002, respectively. We observed different association for H63D allele with iron overload (OR 1.54, CI 95 %1.16-2.03) and none in allele C282Y. Although values averages were different, the extreme dispersion of serum ferritin not showed statistically significant differences between H63D and C282Y alleles and ferritin concentrations. The male unrelated blood donors from Mexico City with iron overload prevalence of 13.8% hold similarities with other populations from Europe o America continent, respecting the allele frequency H63D. Nevertheless, allele frequency C282Y is lower than that observed in descendents from northern Europe. We have not observed statistic difference of SF or iron overload frequency by effect of both alleles.
    Annals of hepatology: official journal of the Mexican Association of Hepatology 6(1):55-60. · 2.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Angesichts der Vielzahl neuer genetischer Tests sehen sich öffentliche Geldgeber der Forderung gegenüber, in Forschung zu deren Wirksamkeit und Wirtschaftlichkeit zu investieren. Solche Untersuchungen rentieren sich aber nur, wenn die daraus gewonnenen Ergebnisse einen relevanten Einfluss auf die Versorgungspraxis haben. Eine Obergrenze für den Wert zusätzlicher Informationen, die die Entscheidungsgrundlage für die Erstattung einzelner Gentests verbessern würden, ist durch den Erwartungswert perfekter Information (Expected Value of Perfect Information, EVPI) gegeben. Die vorliegende Studie illustriert die Bedeutung des EVPI auf Grundlage einer probabilistischen Kosteneffektivitätsanalyse des Screenings auf hereditäre Hämochromatose bei Männern in Deutschland. Hier ist die Einführung eines Bevölkerungsscreenings bei Schwellenwerten von 50.000 oder 100.000 Euro pro gewonnenem Lebensjahr kaum zu empfehlen, und auch der maximal erreichbare Nutzen weiterer Forschung, die zur Revidierung dieser Entscheidung führen könnte, ist gering: Bei den genannten Schwellenwerten beträgt der EVPI 500.000 beziehungsweise 2,2 Mio. Euro. Eine Analyse des EVPI für einzelne Parameter(-gruppen) zeigt, dass Studien über die Adhärenz zur präventiven Phlebotomie den größten potenziellen Nutzen haben. Der Informationswert hängt auch von methodischen Annahmen zum Zeithorizont der Berechnung ab sowie von Szenarien zur Zahl der betroffenen Patienten und der Wirtschaftlichkeit des Screenings.
    Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 05/2012; 55(5). DOI:10.1007/s00103-012-1474-7 · 1.01 Impact Factor
Show more